Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.32 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.32 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.32 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23389921 | 1.00 | TSHR (0.33) | TSHRBRD4GAASLC6A1GABRA5 | |
| SCHEMBL2918911 | 0.89 | CXCR4 (0.35) | TSHRBRD4GAASLC6A1GABRA5 | |
| Acrylamide SCHEMBL28873384 | 0.88 | ALDH1A1 (0.31) | TSHR | |
| SCHEMBL15638009 | 0.84 | — | — | |
| SCHEMBL2910104 | 0.84 | EPHX1 (0.34) | TSHRBRD4GAASLC6A1GABRA5 | |
| SCHEMBL172322 | 0.82 | MGAM (0.38) | GAAMGAMSIMGAM2 | |
| SCHEMBL123309 | 0.82 | MGAM (0.38) | GAAMGAMSIMGAM2 | |
| SCHEMBL27801266 | 0.82 | TSHR (0.40) | TSHRLTA4HCHRNB2CHRNA4LMNA | |
| SCHEMBL27779832 | 0.81 | MIF (0.33) | TSHRSLC6A1GABRA5GABRB2SLC6A12 | |
| SCHEMBL20296636 | 0.81 | SLC6A1 (0.30) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115318113-B | Nanofiltration membrane and preparation method and application thereof | 清华大学 | 2023-10-31 | — | — | CN | claimed |
| CN-115318113-A | Nanofiltration membrane and preparation method and application thereof | 清华大学 | 2022-11-11 | — | — | CN | claimed |
| CN-101641350-A | Dibenzo [ b ] | ARYX THERAPEUTICS INC US | 2010-02-03 | — | — | CN | claimed |
| EP-4289845-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2023-12-13 | — | — | EP | disclosed |
| CN-115318113-B | Nanofiltration membrane and preparation method and application thereof | 清华大学 | 2023-10-31 | — | — | CN | disclosed |
| CN-115318113-A | Nanofiltration membrane and preparation method and application thereof | 清华大学 | 2022-11-11 | — | — | CN | disclosed |
| US-10017509-B2 | Macrocylic pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-10 | — | — | US | disclosed |
| WO-2018092034-A1 | NOVEL IN-VIVO PROBE FOR REAL TIME LONGITUDINAL MONITORING OF INDUCIBLE NITRIC-OXIDE SYNTHASE IN LIVING CELLS AND ANIMALS | PANDA KOUSTUBH (IN) | 2018-05-24 | — | — | WO | disclosed |
| EP-3126364-B1 | MACROCYLIC PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-07 | — | — | EP | disclosed |
| CN-106536491-A | Benzoxazinone amides as mineralocorticoid receptor modulators | 阿斯利康(瑞典)有限公司 | 2017-03-22 | — | — | CN | disclosed |
| EP-2632465-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2015-12-30 | — | — | EP | disclosed |
| US-20080255088-A1 | DIBENZO[b,f][1,4]OXAZAPINE COMPOUNDS | PROTOCELL THERAPEUTICS INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255088-A1 | DIBENZO[b,f][1,4]OXAZAPINE COMPOUNDS | PROTOCELL THERAPEUTICS INC. | 2008-10-16 | — | — | US | disclosed |
| WO-2008112900-A1 | DIBENZO[B,F][1,4]OXAZAPINE COMPOUNDS | ARYX THERAPEUTICS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112900-A1 | DIBENZO[B,F][1,4]OXAZAPINE COMPOUNDS | ARYX THERAPEUTICS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20060189591-A1 | Five-membered heterocyclic derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1621537-A1 | FIVE-MEMBERED HETEROCYCLIC DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
| EP-0196866-A2 | Preparation process of alpha-L-aspartyl-L-phenylalanine methyl ester or hydrochloride thereof | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1986-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | TSHR 4631/4885BRD4 848/4885GAA 3552/4885 |
| US-20060189591-A1 | Five-membered heterocyclic derivative | PTGS1, PTGIS, PTGS2 | TSHR 4671/4885BRD4 500/4885GAA 3879/4885 |
| US-10017509-B2 | Macrocylic pyrimidine derivatives | EEF2K, VPS26B, VPS28 | TSHR 4781/4885BRD4 739/4885GAA 713/4885 |
| US-20080255088-A1 | DIBENZO[b,f][1,4]OXAZAPINE COMPOUNDS | DBH, DRD4, PSEN1 | TSHR 2025/4885BRD4 208/4885GAA 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.